$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000092706624000090 Filed on May 02, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$3.187B	$3.071B	$3.146B
YoY Change	6.21%	6.89%	7.85%
Cost Of Revenue	$2.142B	$2.079B	$2.138B
YoY Change	4.21%	1.01%	2.38%
Gross Profit	$1.044B	$991.6M	$1.007B
YoY Change	10.58%	21.74%	21.63%
Gross Profit Margin	32.77%	32.29%	32.02%
Selling, General & Admin	$367.8M	$362.5M	$401.5M
YoY Change	1.05%	9.31%	5.73%
% of Gross Profit	35.22%	36.56%	39.85%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$175.7M	$187.1M	$195.3M
YoY Change	-4.36%	5.06%	0.62%
% of Gross Profit	16.82%	18.87%	19.38%
Operating Expenses	$543.5M	$549.6M	$596.7M
YoY Change	-0.76%	7.82%	4.0%
Operating Profit	$506.4M	$483.8M	$410.6M
YoY Change	24.95%	55.26%	61.39%
Interest Expense	-$92.27M	-$92.74M	-$90.83M
YoY Change	-2.93%	-1.3%	-8.38%
% of Operating Profit	-18.22%	-19.17%	-22.12%
Other Income/Expense, Net	-$27.48M	-$12.64M	-$4.652M
YoY Change	-2101.38%	-436.91%	-40.34%
Pretax Income	$371.4M	$371.8M	$289.1M
YoY Change	25.83%	73.23%	95.99%
Income Tax	$71.69M	$65.81M	$58.50M
% Of Pretax Income	19.3%	17.7%	20.24%
Net Earnings	$222.7M	$239.6M	$150.7M
YoY Change	24.62%	107.4%	121.23%
Net Earnings / Revenue	6.99%	7.8%	4.79%
Basic Earnings Per Share	$2.56	$2.73
Diluted Earnings Per Share	$2.50	$2.65	$1.62
COMMON SHARES
Basic Shares Outstanding	87.70M shares	87.70M shares	91.30M shares
Diluted Shares Outstanding	88.95M shares	90.55M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$469.0M	$403.5M	$439.6M
YoY Change	21.51%	-1.98%	20.06%
Cash & Equivalents	$416.5M	$345.1M	$380.1M
Short-Term Investments	$52.47M	$58.34M	$59.50M
Other Short-Term Assets	$169.9M	$191.1M	$187.2M
YoY Change	-8.08%	4.07%	7.76%
Inventory	$126.8M	$145.8M	$143.1M
Prepaid Expenses
Receivables	$2.303B	$2.595B	$1.987B
Other Receivables	$420.6M	$396.4M	$422.7M
Total Short-Term Assets	$3.467B	$3.684B	$3.138B
YoY Change	15.49%	21.19%	-0.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.982B	$3.026B	$3.074B
YoY Change	-5.58%	-5.91%	-5.62%
Goodwill	$7.201B	$7.230B	$7.113B
YoY Change	1.34%	1.97%	0.51%
Intangibles	$191.5M	$201.4M	$203.2M
YoY Change	-0.19%	7.86%	11.24%
Long-Term Investments	$485.5M	$540.3M	$593.7M
YoY Change	-24.06%	88.73%	115.56%
Other Assets	$240.5M	$262.4M	$271.3M
YoY Change	-23.41%	-9.91%	-14.05%
Total Long-Term Assets	$13.56B	$13.75B	$13.76B
YoY Change	-2.85%	0.43%	-0.13%
TOTAL ASSETS
Total Short-Term Assets	$3.467B	$3.684B	$3.138B
Total Long-Term Assets	$13.56B	$13.75B	$13.76B
Total Assets	$17.03B	$17.43B	$16.89B
YoY Change	0.39%	4.2%	-0.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$493.5M	$489.9M	$514.5M
YoY Change	15.34%	9.36%	7.24%
Accrued Expenses	$1.050B	$1.023B	$1.147B
YoY Change	2.43%	0.98%	5.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$538.0M	$127.6M	$123.3M
YoY Change	432.07%	-47.31%	-46.72%
Total Short-Term Liabilities	$2.995B	$2.583B	$2.642B
YoY Change	24.61%	0.7%	0.86%
LONG-TERM LIABILITIES
Long-Term Debt	$8.452B	$9.001B	$8.268B
YoY Change	-1.71%	6.93%	-4.88%
Other Long-Term Liabilities	$179.0M	$179.8M	$183.1M
YoY Change	-2.25%	79.4%	73.97%
Total Long-Term Liabilities	$179.0M	$179.8M	$183.1M
YoY Change	-2.25%	79.4%	73.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.995B	$2.583B	$2.642B
Total Long-Term Liabilities	$179.0M	$179.8M	$183.1M
Total Liabilities	$14.60B	$14.79B	$14.15B
YoY Change	1.89%	3.4%	-3.76%
SHAREHOLDERS EQUITY
Retained Earnings	$1.061B	$837.9M	$598.3M
YoY Change	126.28%	188.91%	242.88%
Common Stock	$383.3M	$428.3M	$509.9M
YoY Change	-31.03%	-27.45%	-16.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$615.9M	$240.1M	$0.00
YoY Change
Treasury Stock Shares
Shareholders Equity	$632.9M	$926.0M	$1.056B
YoY Change
Total Liabilities & Shareholders Equity	$17.03B	$17.43B	$16.89B
YoY Change	0.39%	4.2%	-0.2%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	$222.7M	$239.6M	$150.7M
YoY Change	24.62%	107.4%	121.23%
Depreciation, Depletion And Amortization	$175.7M	$187.1M	$195.3M
YoY Change	-4.36%	5.06%	0.62%
Cash From Operating Activities	$798.8M	-$134.8M	$485.2M
YoY Change	77.48%	-129.15%	41.16%
INVESTING ACTIVITIES
Capital Expenditures	$124.7M	$121.0M	$159.0M
YoY Change	0.18%	-18.07%	-18.07%
Acquisitions
YoY Change
Other Investing Activities	-$37.03M	-$94.19M	-$9.322M
YoY Change	-83.36%	-402.27%	-51.51%
Cash From Investing Activities	-$161.8M	-$215.2M	-$168.3M
YoY Change	-53.4%	84.66%	-21.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-563.3M	$319.3M	-403.2M
YoY Change	481.7%	-215.73%	74.64%
NET CHANGE
Cash From Operating Activities	798.8M	-$134.8M	485.2M
Cash From Investing Activities	-161.8M	-$215.2M	-168.3M
Cash From Financing Activities	-563.3M	$319.3M	-403.2M
Net Change In Cash	73.79M	-$33.85M	-86.34M
YoY Change	1098.33%	-146.75%	-14.04%
FREE CASH FLOW
Cash From Operating Activities	$798.8M	-$134.8M	$485.2M
Capital Expenditures	$124.7M	$121.0M	$159.0M
Free Cash Flow	$674.1M	-$255.9M	$326.2M
YoY Change	107.03%	-181.26%	117.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89822000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88824000	shares
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024Q1	dva	Corporate Integrity Agreement Period CorporateIntegrityAgreementPeriod	P5Y
CY2024Q1	us-gaap	Other Income OtherIncome	129023000	usd
CY2023Q1	us-gaap	Other Income OtherIncome	112665000	usd
CY2024Q1	us-gaap	Revenues Revenues	3070555000	usd
CY2023Q1	us-gaap	Revenues Revenues	2872699000	usd
CY2024Q1	dva	Patient Care Costs PatientCareCosts	2078976000	usd
CY2023Q1	dva	Patient Care Costs PatientCareCosts	2058189000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	362480000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	331614000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	187083000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	178071000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	6682000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	6820000	usd
CY2024Q1	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	35147000	usd
CY2023Q1	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	0	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	2586710000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	2561054000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	483845000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	311645000	usd
CY2024Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	99418000	usd
CY2023Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	100774000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12641000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3752000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	371786000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	214623000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65806000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43955000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	305980000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	170668000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	66331000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	55121000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	239649000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	115547000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.73
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.28
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.65
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.25
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	87775000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90497000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90547000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92483000	shares
CY2024Q1	us-gaap	Profit Loss ProfitLoss	305980000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	170668000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	13317000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-3539000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	21628000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	15742000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-39720000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	33561000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-48031000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	14280000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	257949000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	184948000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	66331000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	55121000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	191618000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	129827000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	345131000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	380063000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	85650000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	84571000	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	10611000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11610000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2594675000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1986856000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	145808000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	143105000	usd
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	396399000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	422669000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	105479000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	102645000	usd
CY2024Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	6387000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	3683753000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3137906000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	5921761000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	5759514000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3026170000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3073533000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2487158000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2501364000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	37053000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	38445000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	201433000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	203224000	usd
CY2024Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	492541000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	545848000	usd
CY2024Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	47729000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	47890000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	262449000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	271253000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	7229702000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	7112560000	usd
CY2024Q1	us-gaap	Assets Assets	17430935000	usd
CY2023Q4	us-gaap	Assets Assets	16893578000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	489883000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	514533000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	859604000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	828878000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	622127000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	752598000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	401371000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	394399000	usd
CY2024Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	127616000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	123299000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	82500000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	28507000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2583101000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2642214000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2311902000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2330389000	usd
CY2024Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	9000594000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8268334000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	179806000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	183074000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	719545000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	726217000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	14794948000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	14150228000	usd
CY2024Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1503474000	usd
CY2023Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1499288000	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89822000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88824000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	90000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	89000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	428202000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	509804000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	837937000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	598288000	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2119000	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	240117000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100115000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-52084000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	925997000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1056097000	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	206516000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	187965000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1132513000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1244062000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17430935000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16893578000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	305980000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	170668000	usd
CY2024Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	187083000	usd
CY2023Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	178071000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	24542000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	25373000	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3318000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3621000	usd
CY2024Q1	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-18531000	usd
CY2023Q1	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-3044000	usd
CY2024Q1	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	35147000	usd
CY2023Q1	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	0	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-7639000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-5864000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	561281000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-81850000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1929000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2758000	usd
CY2024Q1	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	13044000	usd
CY2023Q1	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-66595000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1922000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	615000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-14162000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-20535000	usd
CY2024Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-135041000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-74144000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	27237000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-6486000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	60557000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	39251000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-8263000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-5516000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-134836000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	462557000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	121015000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	147705000	usd
CY2024Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	105163000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	usd
CY2024Q1	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	7040000	usd
CY2023Q1	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	13474000	usd
CY2024Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	309000	usd
CY2023Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	25000000	usd
CY2024Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	2975000	usd
CY2023Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	4643000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	300000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	50258000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	4547000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	3856000	usd
CY2024Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	460000	usd
CY2023Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	7904000	usd
CY2024Q1	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	2829000	usd
CY2023Q1	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	1120000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-215206000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-116544000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1290255000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	611829000	usd
CY2024Q1	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	554544000	usd
CY2023Q1	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	880552000	usd
CY2024Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	99000	usd
CY2023Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	7000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	250961000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2024Q1	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	77348000	usd
CY2023Q1	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	54837000	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	86488000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7902000	usd
CY2024Q1	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	3725000	usd
CY2023Q1	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	4725000	usd
CY2024Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2023Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	50832000	usd
CY2024Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	5221000	usd
CY2023Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	319319000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-275912000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3130000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2307000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-33853000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	72408000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	464634000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	338989000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	430781000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	411397000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	239649000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	115547000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	87775000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	90497000	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2772000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1986000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90547000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92483000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.73
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.28
CY2024Q1	us-gaap	Revenues Revenues	3070555000	usd
CY2023Q1	us-gaap	Revenues Revenues	2872699000	usd
CY2024Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	19450000	usd
CY2023Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	12821000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.65
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.25
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	391000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1295000	shares
CY2024Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	22014000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	36326000	usd
CY2024Q1	us-gaap	Marketable Securities MarketableSecurities	58340000	usd
CY2023Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	22109000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	37391000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	59500000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	7011000	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	10611000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	7110000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11610000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	15003000	usd
CY2024Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	47729000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	14999000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	47890000	usd
CY2024Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	22014000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	36326000	usd
CY2024Q1	us-gaap	Marketable Securities MarketableSecurities	58340000	usd
CY2023Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	22109000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	37391000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	59500000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7076610000	usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	25723000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	26083000	usd
CY2023	us-gaap	Goodwill Translation And Purchase Accounting Adjustments GoodwillTranslationAndPurchaseAccountingAdjustments	36310000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	7112560000	usd
CY2024Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	137290000	usd
CY2024Q1	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	1687000	usd
CY2024Q1	us-gaap	Goodwill Translation And Purchase Accounting Adjustments GoodwillTranslationAndPurchaseAccountingAdjustments	-18461000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	7229702000	usd
CY2024Q1	us-gaap	Goodwill Gross GoodwillGross	7376197000	usd
CY2024Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	146495000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	7229702000	usd
CY2024Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	492541000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	545848000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9179476000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8445980000	usd
CY2024Q1	dva	Discount Premium And Deferred Financing Costs DiscountPremiumAndDeferredFinancingCosts	51266000	usd
CY2023Q4	dva	Discount Premium And Deferred Financing Costs DiscountPremiumAndDeferredFinancingCosts	54347000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	214623000	usd
CY2024Q1	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	9128210000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	8391633000	usd
CY2024Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	127616000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	123299000	usd
CY2024Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	9000594000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8268334000	usd
CY2024Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0451
CY2024Q1	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0469
CY2024Q1	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.50
CY2024Q1	dva	Long Term Debt Percentage Bearing Economically Fixed Interest Rate LongTermDebtPercentageBearingEconomicallyFixedInterestRate	0.88
CY2024Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">contingencies</span><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, governmental investigations (which frequently arise from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits) and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of March 31, 2024 and December 31, 2023, the Company’s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Governmental Inquiries and Related Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2017 U.S. Attorney Colorado Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2017, the U.S. Attorney’s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company’s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter currently includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a Civil Investigative Demand (CID) pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. The Company is engaged in discussions with the U.S. Attorney's Office and the Civil Division of the United States Department of Justice to resolve this matter. The Company can make no assurance as to the final outcome. The Company has reserved $40,000 for this matter, which includes any potential payment of attorneys' fees. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 U.S. Attorney New Jersey Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2020, the U.S. Attorney’s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney’s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company’s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney’s Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Doe v. DaVita Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney’s Office for the Eastern District of Pennsylvania notified the U.S. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Bayne v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. On November 8, 2023, the private party relator filed a fourth amended complaint. On November 29, 2023, the Company filed a motion to dismiss the fourth amended complaint. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 California Department of Insurance Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020 and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company’s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients’ decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 District of Columbia Office of Attorney General Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In January 2023, the Office of the Attorney General for the District of Columbia issued a CID to the Company in connection with an antitrust investigation into the AKF. The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company’s communications with AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2024 Federal Trade Commission Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2024, the Company received from the Federal Trade Commission (FTC) two CIDs in connection with an industry investigation under Section 5 of the Federal Trade Commission Act regarding the acquisition of Medical Director services and provision of dialysis services. The CIDs cover the period from January 1, 2016 to the present and generally seek information relating to restrictive covenants, such as non-competes, with physicians. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies, many of which relate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Antitrust Indictment and Putative Class Action Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company’s favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita Inc. and its former chief executive officer were added as defendants in a consolidated putative class action complaint in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Outpatient Medical Center Employee Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company between February 1, 2012 and January 5, 2021. On September 26, 2022, the court denied the </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's motion to dismiss. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> * </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 8, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company’s business, results of operations, financial condition, cash flows or reputation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> * *</span></div>
CY2019Q4	dva	Corporate Integrity Agreement Expiration Date CorporateIntegrityAgreementExpirationDate	2019-10-22
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	189601000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2021Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	2000000000	usd
CY2024Q1	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	59521000	usd
CY2024Q1	dva	Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average Ebitda Multiple PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple	195000000	usd
CY2024Q1	us-gaap	Revenues Revenues	3070555000	usd
CY2023Q1	us-gaap	Revenues Revenues	2872699000	usd
CY2024Q1	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	30390000	usd
CY2023Q1	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	24588000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	483845000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	311645000	usd
CY2024Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	99418000	usd
CY2023Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	100774000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12641000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3752000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	371786000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	187083000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	178071000	usd
CY2024Q1	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	121015000	usd
CY2023Q1	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	147705000	usd
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0000927066-24-000090-index-headers.html	Edgar Link	pending
0000927066-24-000090-index.html	Edgar Link	pending
0000927066-24-000090.txt	Edgar Link	pending
0000927066-24-000090-xbrl.zip	Edgar Link	pending
dva-20240331.htm	Edgar Link	pending
dva-20240331.xsd	Edgar Link	pending
dva-20240331_g1.jpg	Edgar Link	pending
dva-33124ex31110xq.htm	Edgar Link	pending
dva-33124ex31210xq.htm	Edgar Link	pending
dva-33124ex32110xq.htm	Edgar Link	pending
dva-33124ex32210xq.htm	Edgar Link	pending
ex101-2024formpsuawardagre.htm	Edgar Link	pending
ex102-2024formrsuawardagre.htm	Edgar Link	pending
ex103-2024formssarawardagr.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
dva-20240331_cal.xml	Edgar Link	unprocessable
dva-20240331_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dva-20240331_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
dva-20240331_pre.xml	Edgar Link	unprocessable
dva-20240331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2024 Q2 Form 10-Q Financial Statement

#000092706624000090 Filed on May 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2024 Q2 Form 10-Q Financial Statement

#000092706624000090 Filed on May 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva